Log In
BCIQ
Print this Print this
 

Vernakalant (oral) (RSD1235 oral)

Also known as: RSD1235 CR oral

  Manage Alerts
Collapse Summary General Information
Company Cardiome Pharma Corp.
DescriptionControlled-release formulation of mixed ion channel antagonist
Molecular Target Potassium channel ; Sodium channel
Mechanism of ActionK channel blocker; Na channel blocker
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationFibrillation
Indication DetailsPrevent or slow recurrence of atrial fibrillation (AF); Prevent recurrence of atrial fibrillation (AF)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$800.0M

$60.0M

$640.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

04/13/2009

$800.0M

$60.0M

$640.0M

Get a free BioCentury trial today